Efficacy and safety of dual therapy with daclatasvir and asunaprevir in elderly patients

Table 5 Causes of discontinuation and numbers of patients in whom the study drugs were discontinued due to adverse events in the elderly and non-elderly groups

Elderly patients	Non-elderly patients
16 w Malaise, Anorexia1	18 w Elevation of ALT1
6 w Malaise, Anorexia1	6 w Elevation of ALT1
6 w Elevation of ALT1	2 w Pyrexia1
8 w Elevation of ALT1	3 w Pyrexia
3 w Pyrexia	13 w Sepsis due to hemolytic
4 w Cough	streptococcus1
18 w Development of HCC1	18 w Abdominal fullness1
	2 w Elongation of PT
	3 w Elevation of total bilirubin1
	18 w Development of HCC1
Total 7/56 (12.5%)	9/141 (6.4%)

¹Patients achieved sustained virological response at 24-wk. Level of elevation of ALT and total bilirubin at which the drug was discontinued: 200 INU (5-folds of normal) for ALT and 3.0 mg/dL for total bilirubin. HCC: Hepatocellular carcinoma; ALT: Alanine aminotransferase.